drug · protein
ZEPBOUND
Marketedupdated 6mo ago/ tur-ZEP-ə-tyde /
by $LLY ELI LILLY & Co🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $4.9B
community read0 votes
🐶 often sniffed alongside
top 6Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.
indications
investigational
Obesity
targets
Glucagon-like peptide 1 receptorGastric inhibitory polypeptide receptor
all catalysts(24)
approval · 24
May 13, 2022
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jul 28, 2023
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jul 28, 2023
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 8, 2023
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Mar 28, 2024
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Dec 20, 2024
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Feb 7, 2025
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
May 28, 2025
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Sep 25, 2025
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Sep 25, 2025
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Dec 19, 2025
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 7, 2026
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 7, 2026
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 20, 2026
approval
$LLY1382.75-2.32%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 20, 2026
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Feb 25, 2026
approval
$LLY1382.75-2.32%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Trials studying ZEPBOUND
- phase2A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
- phase4A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
- phase1Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
- phase3A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- phase1A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
- phase3Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
- phase2Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
- phase3A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 13, 2027
174 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (216)
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4228)US 12343382
- Jul 22, 2039method-of-use (U-4227)US 12343382
- Jul 22, 2039method-of-use (U-4231)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4229)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4401)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4309)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4309)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-4377)US 12453755
- Jun 14, 2039method-of-use (U-4385)US 12453755
- Jun 14, 2039method-of-use (U-4386)US 12453755
- Jun 14, 2039method-of-use (U-4378)US 12453755
- Jun 14, 2039method-of-use (U-4386)US 12453755
- Jun 14, 2039method-of-use (U-4381)US 12453755
- Jun 14, 2039method-of-use (U-4380)US 12453755
- Jun 14, 2039method-of-use (U-4377)US 12453755
- Jun 14, 2039method-of-use (U-4378)US 12453755
- Jun 14, 2039method-of-use (U-4386)US 12453755
- Jun 14, 2039method-of-use (U-4376)US 12453755
- Jun 14, 2039method-of-use (U-4383)US 12453755
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
FDA exclusivities (62)
- Dec 19, 2028NPPNew Product (3y)2.1y
- Dec 19, 2028NPPNew Product (3y)2.1y
- Dec 19, 2028NPPNew Product (3y)2.1y
- Dec 19, 2028NPPNew Product (3y)2.1y
- Dec 19, 2028NPPNew Product (3y)2.1y
- Dec 19, 2028NPPNew Product (3y)2.1y
- Dec 19, 2028NPPNew Product (3y)2.1y
- Dec 19, 2028NPPNew Product (3y)2.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Dec 20, 2027I-958Indication (3y)1.1y
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- Oct 18, 2027M-82Method (3y)332d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- May 13, 2027NCENew Chemical Entity (5y)174d
- Nov 8, 2026NPNP
- Nov 8, 2026NPNP
- Nov 8, 2026NPNP
- Nov 8, 2026NPNP
- Nov 8, 2026NPNP
- Nov 8, 2026NPNP
News(10)
- ‘Selling and marketing snake oil’: The debate over compounded GLP-1sProponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH confer…biopharma_dive · 18h ago
- Novo’s CagriSema drives more than 20% weight loss at lower dosesAs Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…biospace · 2d ago
- STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and moreDuring July and August 2025, approximately 1 in 10 U.S. adults reported taking a GLP-1 medication during the previous yearstat · 2d ago
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.stat · 5d ago
- STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and moreA deal for smart-ring maker Oura to acquire a telehealth company is raising conflict-of-interest questions for Eli Lillystat · 5d ago
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 6d ago
- Deep dive: Cardiovascular calamities and catalystsBioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.biospace · 6d ago
- Blackstone bets $1.5B on Pfizer’s obesity drugThe deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.biopharma_dive · 6d ago
- STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and moreThe FDA has shelved the fast-track drug review initiative launched in June 2025 by former Commissioner Marty Makarystat · 6d ago
- STAT+: Most-favored nations policy makes drugmakers rethink launches abroadDrug companies seem to be looking for workarounds to protect their U.S. sales against Trump's "most-favored nations" policy:stat · 7d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that